Mental Health Clinics in Blakeslee, PA Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Comprehensive Psychological Services Psychologist Medicare: Not Enrolled in Medicare Practice Location: 274 Route 970, Blakeslee Square, Blakeslee, PA 18610 Phone: 570-643-0222 Fax: 570-643-0224 |
Ajbs Behavior Services Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 353 Arthurs Way, Blakeslee, PA 18610 Phone: 570-350-1358 |
News Archive
Diverted medical marijuana use more common among adolescents in substance abuse treatment
A study published in the July 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry found that diverted medical marijuana use among adolescents receiving treatment for substance abuse is very common.
KCI announces agreement to renew existing single-source contracts with KCI's TSS business
Kinetic Concepts, Inc. today announced an agreement with Novation, one of the health care industry's largest supply contracting companies, to renew its existing single-source contracts with KCI's Therapeutic Support Systems business through the end of 2013. Through Novation, KCI provides access to its innovative hospital beds, mattress replacement systems, overlays and bariatric products to more than 30,500 health care institutions across the U.S.
Scripps scientists generate synthetic memory trace
Scripps Research Institute scientists and their colleagues have successfully harnessed neurons in mouse brains, allowing them to at least partially control a specific memory. Though just an initial step, the researchers hope such work will eventually lead to better understanding of how memories form in the brain, and possibly even to ways to weaken harmful thoughts for those with conditions such as schizophrenia and post traumatic stress disorder.
New medicine could reduce number of infants dying from AIDS
A new, strawberry-flavored, granule-form medicine may be a solution for treating infants with AIDs.
Protox' Phase 2 study of PRX302 for treating BPH provides positive results
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.
› Verified 7 days ago